MediWound (MDWD) to Release Earnings on Tuesday

MediWound (NASDAQ:MDWD – Get Rating) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 30th. Analysts expect MediWound to post earnings of ($0.31) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

MediWound (NASDAQ:MDWD – Get Rating) last issued its quarterly earnings data on Thursday, March 16th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.99). The firm had revenue of $11.62 million for the quarter, compared to the consensus estimate of $7.41 million. MediWound had a negative return on equity of 638.40% and a negative net margin of 73.97%. On average, analysts expect MediWound to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

MediWound Trading Down 1.1 %

Shares of MediWound stock opened at $9.67 on Tuesday. The stock has a market capitalization of $89.02 million, a price-to-earnings ratio of -2.52 and a beta of 1.06. MediWound has a 1-year low of $8.05 and a 1-year high of $15.72. The firm’s 50-day moving average price is $11.68 and its two-hundred day moving average price is $11.74.

Hedge Funds Weigh In On MediWound

A number of large investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. acquired a new position in MediWound in the fourth quarter valued at approximately $57,000. Sphera Funds Management LTD. lifted its holdings in MediWound by 47.4% in the first quarter. Sphera Funds Management LTD. now owns 111,127 shares of the biopharmaceutical company’s stock valued at $1,480,000 after buying an additional 35,714 shares during the period. Alyeska Investment Group L.P. acquired a new position in MediWound in the first quarter valued at approximately $1,998,000. Finally, Renaissance Technologies LLC lifted its holdings in MediWound by 3.8% in the second quarter. Renaissance Technologies LLC now owns 475,422 shares of the biopharmaceutical company’s stock valued at $875,000 after buying an additional 17,600 shares during the period. 13.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MDWD. StockNews.com began coverage on shares of MediWound in a research note on Thursday, May 18th. They set a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of MediWound in a research report on Friday, March 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, MediWound has a consensus rating of “Moderate Buy” and a consensus price target of $32.33.

MediWound Company Profile

(Get Rating)

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.